New combo therapy aims to keep insulin flowing in young diabetes patients

NCT ID NCT06455319

First seen Jan 08, 2026 · Last updated May 15, 2026 · Updated 20 times

Summary

This study tests whether a two-step treatment can help young people with newly diagnosed type 1 diabetes keep making their own insulin. First, participants receive a low dose of anti-thymocyte globulin (ATG) to calm the immune system, followed by verapamil to reduce stress on insulin-producing cells. The goal is to preserve natural insulin production and lower blood sugar levels. The trial enrolls 60 people aged 6 to 35 who were diagnosed within the past 100 days.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TYPE 1 DIABETES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Barbara Davis Center for Diabetes

    RECRUITING

    Aurora, Colorado, 80045, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • University of Florida

    RECRUITING

    Gainesville, Florida, 32610, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.